Mohammad Irshad Reza

Mr. Mohammad Irshad Reza

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Life Sciences
Verified
Journal Article
Closed access
SASyed Anees Ahmed
Syed Anees Ahmed
MRMohammad Irshad Reza
Mohammad Irshad Reza
Mohammad ShafiqMohammad Shafiq
Mohammad Shafiq
SKSanjana Kumariya
Sanjana Kumariya
PSPragati Singh
Pragati Singh
JGJiaur R. Gayen
Jiaur R. Gayen

30 May 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
MRMohammad Irshad Reza
Mohammad Irshad Reza
NANilesh Sudhakar Ambhore
Nilesh Sudhakar Ambhore
Asthma is a chronic and multifaceted respiratory condition that affects over 300 million individuals across the globe. It is characterized by persistent inflammation of the airways, which leads to episodes of wheezing, breathlessness, chest tightness, and coughing. The most prevalent form of asthma is classified as Type 2 or T2-high asthma. In this variant, the immune response is heavily driven by eosinophils, mast cells, and T-helper 2 (Th2) cells. These components release a cascade of cytokines, including interleukin-4 (IL-4), interleukin-5 (IL-5), and interleukin-13 (IL-13). This release promotes several processes: the production of immunoglobulin E (IgE), which is integral to allergic responses; the recruitment of eosinophils—white blood cells that contribute to inflammation and tissue damage. Conversely, non-Type 2 or T2-low asthma is typically associated with a different inflammatory profile characterized by neutrophilic inflammation. This type of asthma is driven by T-helper 1 (Th1) and T-helper 17 (Th17) immune responses, which are often present in older adults, smokers, and those suffering from more severe manifestations of the disease. Among asthmatic patients, approximately 80–85% of cases are classified as T2-high asthma, while only 15–20% are T2-low asthma. Treatment of asthma focuses heavily on controlling inflammation. Inhaled corticosteroids remain the cornerstone therapy for managing T2-high asthma. For more severe or treatment-resistant cases, biologic therapies targeting specific inflammatory pathways, such as anti-IgE (omalizumab), anti-IL-5 (mepolizumab, benralizumab), and anti-IL-4/IL-13 (dupilumab), have shown great promise. For T2-low asthma, macrolide antibiotics like azithromycin and other novel therapies are being explored. This article reviews the safety, efficacy, and indications of the currently approved biologics and discusses potential novel biologics for asthma.

26 April 2020 in Current Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
IBIshfaq Ahmad Bhat
Ishfaq Ahmad Bhat
SKShaheen Wasil Kabeer
Shaheen Wasil Kabeer
MRMohammad Irshad Reza
Mohammad Irshad Reza
RMReyaz Hassan Mir
Reyaz Hassan Mir
MDMuhammad Ovais Dar
Muhammad Ovais Dar
Background: AdipoRon is the first synthetic analog of endogenous adiponectin, an adipose tissue-derived hormone. AdipoRon possesses pharmacological properties similar to adiponectin and its ability to bind and activate the adipoR1 and adipoR2 receptors makes it a suitable candidate for the treatment of a multitude of disorders.Objective: In the present review, an attempt was made to compile and discuss the efficacy of adipoRon against various disorders.Results: AdipoRon is a drug that acts not only in metabolic diseases but in other conditions unrelated to energy metabolism. It is well- reported that adipoRon exhibits strong anti-obesity, anti-diabetic, anticancer, anti-depressant, anti-ischemic, anti-hypertrophic properties and also improves conditions like post-traumatic stress disorder, anxiety, and systemic sclerosis.Conclusion: A lot is known about its effects in experimental systems, but the translation of this knowledge to the clinic requires studies which, for many of the potential target conditions, have yet to be carried out. The beneficial effects of AdipoRon in novel clinical conditions will suggest an underlying pathophysiological role of adiponectin and its receptors in previously unsuspected settings.

24 February 2025 in Immunological Reviews
Verified
Journal Article
Open access
Maria FordMaria Ford
Maria Ford
MRMohammad Irshad Reza
Mohammad Irshad Reza
ARAnushka Ruwanpathirana
Anushka Ruwanpathirana
SVSathish Venkatachalem
Sathish Venkatachalem
RBRodney D. Britt
Rodney D. Britt
Asthma has become more appreciated for its heterogeneity with studies identifying type 2 and non‐type 2 phenotypes/endotypes that ultimately lead to airflow obstruction, airway hyperresponsiveness, and remodeling. The pro‐inflammatory environment in asthma influences airway smooth muscle (ASM) structure and function. ASM has a vast repertoire of inflammatory receptors that, upon activation, contribute to prominent features in asthma, notably immune cell recruitment and activation, hypercontractility, proliferation, migration, and extracellular matrix protein deposition. These pro‐inflammatory responses in ASM can be mediated by both type 2 (e.g., IL‐4, IL‐13, and TSLP) and non‐type 2 (e.g., TNFα, IFNγ, IL‐17A, and TGFβ) cytokines, highlighting roles for ASM in type 2 and non‐type 2 asthma phenotypes/endotypes. In recent years, there has been considerable advances in understanding how pro‐inflammatory cytokines promote ASM dysfunction and impair responsiveness to asthma therapy, corticosteroids and long‐acting β2‐adrenergic receptor agonists (LABAs). Transcriptomic analyses on human ASM cells and tissues have expanded our knowledge in this area but have also raised new questions regarding ASM and its role in asthma. In this review, we discuss how pro‐inflammatory cytokines, corticosteroids, and LABAs affect ASM structure and function, with particular focus on changes in gene expression and transcriptional programs in type 2 and non‐type 2 asthma.

1 February 2021 in Phytomedicine Plus
Verified
Journal Article
Open access
SASyed Anees Ahmed
Syed Anees Ahmed
MRMohammad Irshad Reza
Mohammad Irshad Reza
AHAthar Husain
Athar Husain
PSPragati Singh
Pragati Singh
JGJiaur R. Gayen
Jiaur R. Gayen

14 September 2021 in Current Drug Metabolism
Verified
Journal Article
Closed access
PDF file
SASyed Anees Ahmed
Syed Anees Ahmed
MRMohammad Irshad Reza
Mohammad Irshad Reza
PSPragati Singh
Pragati Singh
GTGanesh K. Thombre
Ganesh K. Thombre
JGJiaur R. Gayen
Jiaur R. Gayen
Background: The underlying cause of major neurodegenerative disorders remains a healthcare mystery. The thoroughly investigated causes include oxidative stress, inflammation, environmental factor, mitochondrial dysfunction, and irregular neuronal protein aggregation. Withania somnifera has been used for more than 2500 years as a useful medicinal plant to improve disease defense, prevent aging, rejuvenate the body in a vulnerable situation, and generate a feeling of mental well-being. However, a persuasive paper emphasizing its neuroprotective nature is missing. Objective: In the current review, we have delineated the protective role of W. somnifera against various neurological disorders and its progress in delivery systems. Methods: The database used in the retrieval of data were PubMed, Scopus, Science direct, and SciFinder. The keywords used were W. somnifera, Ashwagandha, neuroprotective activities, etc. The principal source of the data retrieval includes research articles, review papers, and short communications from reputed publishers, including the New England Journal of Medicine, Elsevier, Nature, Springer, and Taylor & Francis. Results: After an extensive literature review, we found that W. somnifera mitigates various neurological disorders, including Parkinson's disease, Alzheimer's disease, Huntington disease, tardive dyskinesia, stroke, and anxiety. Furthermore, natural compounds in nano sizes range possess better neuroprotective activity. Consequently, polymeric nanomicelles, nanoparticles, and nanofibers of natural products are used in the treatment of neurodegenerative diseases. Conclusion: The current review substantially deciphered the protective role of W. somnifera against various neurological disorders. However, future studies are further required better to understand the molecular mechanisms behind their neuroprotective nature.